{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:51:34Z","timestamp":1794667894352,"version":"4.9.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T00:00:00Z","timestamp":1614038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T00:00:00Z","timestamp":1614038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Immunotherapy has raised high expectations in the treatment of virtually every cancer. Many current efforts are focused on ensuring the efficient delivery of active cytotoxic cells to tumors. It is assumed that, once these active cytotoxic cells are correctly engaged to cancer cells, they will unfailingly eliminate the latter, provided that inhibitory factors are in check. T cell bispecific antibodies (TCBs) and chimeric antigen receptors (CARs) offer an opportunity to test this assumption. Using TCB and CARs directed against HER2, here we show that disruption of interferon-gamma signaling confers resistance to killing by active T lymphocytes. The kinase JAK2, which transduces the signal initiated by interferon-gamma, is a component repeatedly disrupted in several independently generated resistant models. Our results unveil a seemingly widespread strategy used by cancer cells to resist clearance by redirected lymphocytes. In addition, they open the possibility that long-term inhibition of interferon-gamma signaling may impair the elimination phase of immunoediting and, thus, promote tumor progression.<\/jats:p>","DOI":"10.1038\/s41467-021-21445-4","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T11:14:21Z","timestamp":1614078861000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7076-2666","authenticated-orcid":false,"given":"Enrique J.","family":"Arenas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9477-1396","authenticated-orcid":false,"given":"Alex","family":"Mart\u00ednez-Sabadell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6097-7572","authenticated-orcid":false,"given":"Irene","family":"Rius Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8128-9528","authenticated-orcid":false,"given":"Macarena","family":"Rom\u00e1n Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Escorihuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Luque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Alberto","family":"Fajardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alena","family":"Gros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7594-7280","authenticated-orcid":false,"given":"Christian","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0504-0664","authenticated-orcid":false,"given":"Joaqu\u00edn","family":"Arribas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,23]]},"reference":[{"key":"21445_CR1","first-page":"2825","volume":"16","author":"M-E Goebeler","year":"2020","unstructured":"Goebeler, M.-E. & Bargou, R. C. T cell-engaging therapies\u2014BiTEs and beyond. Nat. Rev. Clin. Oncol. 16, 2825\u2013434 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"21445_CR2","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1016\/S1470-2045(19)30823-X","volume":"21","author":"AK Singh","year":"2020","unstructured":"Singh, A. K. & McGuirk, J. P. CAR T cells: continuation in a revolution of immunotherapy. Lancet Oncol. 21, e168\u2013e178 (2020).","journal-title":"Lancet Oncol."},{"key":"21445_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.copbio.2019.11.020","volume":"65","author":"C Rader","year":"2019","unstructured":"Rader, C. Bispecific antibodies in cancer immunotherapy. Curr. Opin. Biotechnol. 65, 9\u201316 (2019).","journal-title":"Curr. Opin. Biotechnol."},{"key":"21445_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/antib8030041","volume":"8","author":"Strohl","year":"2019","unstructured":"Strohl & Naso. Bispecific T-cell redirection versus chimeric antigen receptor (CAR)-T cells as approaches to kill cancer cells. Antibodies 8, 41\u201368 (2019).","journal-title":"Antibodies"},{"key":"21445_CR5","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","volume":"18","author":"AF Labrijn","year":"2019","unstructured":"Labrijn, A. F., Janmaat, M. L., Reichert, J. M. & Parren, P. W. H. I. Bispecific antibodies: a mechanistic review of the pipeline. Nat. Rev. Drug Discov. 18, 585\u2013608 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"21445_CR6","doi-asserted-by":"publisher","first-page":"eaaw2127","DOI":"10.1126\/scitranslmed.aaw2127","volume":"11","author":"L Schultz","year":"2019","unstructured":"Schultz, L., Mackall, C. & Driving, C. A. R. T cell translation forward. Sci. Transl. Med. 11, eaaw2127 (2019).","journal-title":"Sci. Transl. Med."},{"key":"21445_CR7","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1146\/annurev-med-062617-035821","volume":"70","author":"RA Clynes","year":"2019","unstructured":"Clynes, R. A. & Desjarlais, J. R. Redirected T cell cytotoxicity in cancer therapy. Annu. Rev. Med. 70, 437\u2013450 (2019).","journal-title":"Annu. Rev. Med."},{"key":"21445_CR8","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1158\/2159-8290.CD-18-0297","volume":"8","author":"CY Slaney","year":"2018","unstructured":"Slaney, C. Y., Wang, P., Darcy, P. K. & Kershaw, M. H. CARs versus BiTEs: a comparison between T cell-redirection strategies for cancer treatment. Cancer Discov. 8, 924\u2013934 (2018).","journal-title":"Cancer Discov."},{"key":"21445_CR9","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64\u201373 (2018).","journal-title":"N. Engl. J. Med."},{"key":"21445_CR10","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.blre.2018.02.004","volume":"32","author":"A Thakur","year":"2018","unstructured":"Thakur, A., Huang, M. & Lum, L. G. Bispecific antibody based therapeutics: strengths and challenges. Blood Rev. 32, 339\u2013347 (2018).","journal-title":"Blood Rev."},{"key":"21445_CR11","first-page":"372","volume":"16","author":"NN Shah","year":"2019","unstructured":"Shah, N. N. & Fry, T. J. Mechanisms of resistance to CAR T cell therapy. Nat. Rev. Clin. Oncol. 16, 372\u2013385 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"21445_CR12","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian, H. et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N. Engl. J. Med. 376, 836\u2013847 (2017).","journal-title":"N. Engl. J. Med"},{"key":"21445_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 20, 31\u201342 (2019).","journal-title":"Lancet Oncol."},{"key":"21445_CR14","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1158\/1078-0432.CCR-18-2743","volume":"25","author":"N Bouchkouj","year":"2019","unstructured":"Bouchkouj, N. et al. FDA approval summary: axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma. Clin. Cancer Res. 25, 1702\u20131708 (2019).","journal-title":"Clin. Cancer Res."},{"key":"21445_CR15","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq, S., Hackett, C. S. & Brentjens, R. J. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat. Rev. Clin. Oncol. 17, 147\u2013167 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"21445_CR16","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ccr.2014.02.025","volume":"25","author":"CL Arteaga","year":"2014","unstructured":"Arteaga, C. L. & Engelman, J. A. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 25, 282\u2013303 (2014).","journal-title":"Cancer Cell"},{"key":"21445_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S1535-6108(02)00212-X","volume":"2","author":"SE Moody","year":"2002","unstructured":"Moody, S. E. et al. Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell 2, 11\u201311 (2002).","journal-title":"Cancer Cell"},{"key":"21445_CR18","doi-asserted-by":"publisher","first-page":"eaat1445","DOI":"10.1126\/scitranslmed.aat1445","volume":"10","author":"I Rius Ruiz","year":"2018","unstructured":"Rius Ruiz, I. et al. p95HER2-T cell bispecific antibody for breast cancer treatment. Sci. Transl. Med. 10, eaat1445 (2018).","journal-title":"Sci. Transl. Med."},{"key":"21445_CR19","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ccr.2005.10.012","volume":"8","author":"DA Thomas","year":"2005","unstructured":"Thomas, D. A. & Massagu\u00e9, J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8, 369\u2013380 (2005).","journal-title":"Cancer Cell"},{"key":"21445_CR20","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.immuni.2018.01.006","volume":"48","author":"LK Smith","year":"2018","unstructured":"Smith, L. K. et al. Interleukin-10 directly inhibits CD8+ T cell function by enhancing N-glycan branching to decrease antigen sensitivity. Immunity 48, 299\u2013312 (2018). e5.","journal-title":"Immunity"},{"key":"21445_CR21","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1084\/jem.20050930","volume":"203","author":"I Kryczek","year":"2006","unstructured":"Kryczek, I. et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exp. Med. 203, 871\u2013881 (2006).","journal-title":"J. Exp. Med."},{"key":"21445_CR22","doi-asserted-by":"publisher","first-page":"a028480","DOI":"10.1101\/cshperspect.a028480","volume":"11","author":"E Alspach","year":"2019","unstructured":"Alspach, E., Lussier, D. M. & Schreiber, R. D. Interferon \u03b3 and its important roles in promoting and inhibiting spontaneous and therapeutic cancer immunity. Cold Spring Harb. Perspect. Biol. 11, a028480 (2019).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"21445_CR23","doi-asserted-by":"publisher","first-page":"15623","DOI":"10.1073\/pnas.95.26.15623","volume":"95","author":"SD Der","year":"1998","unstructured":"Der, S. D., Zhou, A., Williams, B. R. & Silverman, R. H. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc. Natl Acad. Sci. USA 95, 15623\u201315628 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"21445_CR24","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature07829","volume":"459","author":"ND Heintzman","year":"2009","unstructured":"Heintzman, N. D. et al. Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature 459, 108\u2013112 (2009).","journal-title":"Nature"},{"key":"21445_CR25","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1158\/2159-8290.CD-19-0813","volume":"10","author":"N Singh","year":"2020","unstructured":"Singh, N. et al. Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction. Cancer Discov. 10, 552\u2013567 (2020).","journal-title":"Cancer Discov."},{"key":"21445_CR26","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1182\/blood.V95.6.2098","volume":"95","author":"A L\u00f6ffler","year":"2000","unstructured":"L\u00f6ffler, A. et al. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 95, 2098\u20132103 (2000).","journal-title":"Blood"},{"key":"21445_CR27","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.3390\/ijms20061283","volume":"20","author":"M-R Benmebarek","year":"2019","unstructured":"Benmebarek, M.-R. et al. Killing mechanisms of chimeric antigen receptor (CAR) T cells. Int. J. Mol. Sci. 20, 1283 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"21445_CR28","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.molimm.2005.03.007","volume":"43","author":"S Offner","year":"2006","unstructured":"Offner, S., Hofmeister, R., Romaniuk, A., Kufer, P. & Baeuerle, P. A. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol. Immunol. 43, 763\u2013771 (2006).","journal-title":"Mol. Immunol."},{"key":"21445_CR29","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/ni1058","volume":"5","author":"MA Purbhoo","year":"2004","unstructured":"Purbhoo, M. A., Irvine, D. J., Huppa, J. B. & Davis, M. M. T cell killing does not require the formation of a stable mature immunological synapse. Nat. Immunol. 5, 524\u2013530 (2004).","journal-title":"Nat. Immunol."},{"key":"21445_CR30","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ccr.2013.04.004","volume":"23","author":"T Kammertoens","year":"2013","unstructured":"Kammertoens, T. & Blankenstein, T. It\u2019s the peptide-MHC affinity, stupid. Cancer Cell 23, 429\u2013431 (2013).","journal-title":"Cancer Cell"},{"key":"21445_CR31","doi-asserted-by":"publisher","first-page":"7308","DOI":"10.4049\/jimmunol.176.12.7308","volume":"176","author":"MA Purbhoo","year":"2006","unstructured":"Purbhoo, M. A. et al. Quantifying and imaging NY-ESO-1\/LAGE-1-derived epitopes on tumor cells using high affinity T cell receptors. J. Immunol. 176, 7308\u20137316 (2006).","journal-title":"J. Immunol."},{"key":"21445_CR32","doi-asserted-by":"publisher","first-page":"5321","DOI":"10.1073\/pnas.89.12.5321","volume":"89","author":"OP Kallioniemi","year":"1992","unstructured":"Kallioniemi, O. P. et al. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc. Natl Acad. Sci. USA 89, 5321\u20135325 (1992).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"21445_CR33","doi-asserted-by":"publisher","first-page":"E2068","DOI":"10.1073\/pnas.1716266115","volume":"115","author":"AJ Davenport","year":"2018","unstructured":"Davenport, A. J. et al. Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity. Proc. Natl Acad. Sci. USA 115, E2068\u2013E2076 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"21445_CR34","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1182\/blood-2017-04-742288","volume":"130","author":"P Bose","year":"2017","unstructured":"Bose, P. & Verstovsek, S. JAK2 inhibitors for myeloproliferative neoplasms: what is next? Blood 130, 115\u2013125 (2017).","journal-title":"Blood"},{"key":"21445_CR35","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.cell.2017.11.010","volume":"172","author":"N Sachs","year":"2018","unstructured":"Sachs, N. et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell 172, 373\u2013382 (2018). e10.","journal-title":"Cell"},{"key":"21445_CR36","first-page":"397","volume":"87","author":"J Yang","year":"2019","unstructured":"Yang, J., Pemberton, A., Morrison, W. I., Connelley, T. & Granzyme, B. Is an essential mediator in CD8+ T Cell Killing of Theileria parva-infected cells. Infect. Immun. 87, 397 (2019).","journal-title":"Infect. Immun."},{"key":"21445_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"21445_CR38","doi-asserted-by":"publisher","unstructured":"Korotkevich, G., Sukhov, V. & Sergushichev, A. Fast gene set enrichment analysis. bioRxiv https:\/\/doi.org\/10.1101\/060012 (2019).","DOI":"10.1101\/060012"},{"key":"21445_CR39","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The molecular signatures database hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21445-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21445-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21445-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T11:07:39Z","timestamp":1669979259000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21445-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,23]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["21445"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-21445-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,23]]},"assertion":[{"value":"28 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.K. declares employment, stock ownership, and patents with Roche. A.G. reports receiving funding from Novartis, VCNBiosciences and Merck KGaA, has received speaker honoraria from Roche, and has consulted for Achilles Therapeutics, Neon Therapeutics, Genentech, PACT Pharma and Oxford Immunotherapy. J.A. has received research funds from Roche, Synthon, Menarini, and Molecular Partners and consultancy honoraria from Menarini. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1237"}}